Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers

Pharmacogenetics

Volumn 6, Issue 6, 1996, Pages 501-512

  Agúndez, José A G ^a   Olivera, Manuela ^a   Ladero, José M ^b,c   Rodriguez Lescure, Alvaro ^c   Ledesma, Maria C ^a   Diaz Rubio, Manuel ^b,c   Meyer, Urs A ^d   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

CYP2D6; hepatocellular carcinoma; NAT2; susceptibility

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; MARKER; SULFADIMIDINE; UNCLASSIFIED DRUG;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REFERENCE VALUES; RISK FACTORS;

EID: 0030481307     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199612000-00003     Document Type: Article

References (56)

1. Adami HO, Hsing AW, McLaughlin JK, Trichopoulos D, Hacker D, Ekbom A, Persson I. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer 1992: 30, 898-902.
2. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994: 264, 1317-1319.
3. Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the aryamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994a: 56, 202-209.
4. Agúndez JAG, Martínez C, Ledesma MC, Ladona MG, Ladero JM, Benítez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994b: 55, 412-417.
5. Agúndez JAG, Ledesma MC, Benítez J, Ladero JM, Rodriguez-Lescure A, Díaz-Rubio E, Díaz-Rubio M. CYP2D6 genes and liver cancer. Lancet 1995a: 345, 830-831.
6. Agúndez JAG, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995b: 57, 265-269.
7. Agúndez JAG, Ladero JM, Olivera M, Abildúa R, Román JM, Benítez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 1995c: 52, 7-11.
8. Agúndez JAG, Olivera M, Martínez C, Ladero JM, Benítez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996: in press.
9. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 1990: 87, 4790-4793.
10. Beral V, Blum H, Buendia MA, Craig JR, Dragani TA, Gao YT, Grisham JW, Hall AJ, Kaldor J, Kew MC, Kirby GM, London WT, Marion PL, Miller AB, Monjardino J, Muller N, Nishioka K, Ozturk M, Tricopoulos D. Hepatitis viruses. In IARC Monographs on the evaluation of carcinogenic risks to humans, Vol 59. Lyon: International Agency for Research on Cancer 1994: 165-221.
11. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991: 88, 5237-5241.
12. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, Castillo R, Rodes J. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989: 2, 1004-1006.
13. Bulpitt CJ. Confidence intervals. Lancet 1987: 1, 494-497
14. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995: 5, 59-63.
15. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991: 1, 4-19.
16. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4(methylmtrosarnino)-1-(3-pyridil)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991: 12, 1197-1201.
17. Degawa M, Stern SJ, Martin MV, Guengerich FP, Fu PP, Ilett KF, Kaderlik RK, Kadlubar FF. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res 1994: 54, 4915-4949.
18. Evans DAP. N-acetyltransferase. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 95-178.
19. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Human Genet 1991: 48, 943-950.
20. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine. N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1990: 39, 188-191.
21. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 1991: 4, 391-407.
22. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL, Meyer UA. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993: 14, 675-678.
23. Heim M, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods Enzymol 1991: 206, 173-183.
24. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988: 948, 37-66.
25. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993: 14, 1633-1638.
26. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant and chimeric NAT2 allozymes. Hum Mol Genet 1994: 3, 729-734.
27. Ilet KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987: 47, 1466-1469.
28. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
29. Kew MC. Hepatitis C virus and hepatocellular carcinoma. FEMS Microbiol Rev 1994: 14, 211-220.
30. Ladero JM, Gonzalez JF, Benítez J, Vargas E, Fernandez MJ, Baki W, Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991: 51, 2098-2100.
31. Lai M, Cheng P, Yang P, Sheu J, Shung J, Chen D. Identification and characterization of intrahepatic hepatitis B virus DNA in HBs Ag seronegative patients with chronic liver disease and hepatocellular carcinoma in Taiwan. Hepatology 1990: 12, 575-581.
32. Lang NP, Chu DZJ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Archiv Surg 1986: 121, 1259-1261.
33. Lee HS, Han CJ, Kim CY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area. Cancer 1993: 72, 2564-2567.
34. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994: 4, 125-134.
35. Martínez C, Agúndez JAG, Olivera M, Martín R, Ladero JM, Benítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995: 5, 207-214.
36. Moller-Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990: 26, 1167-1256.
37. Nalpas B, Driss F, Pol S, Hamelin B, Housset C, Brechot C, Berthelot P. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991: 12, 70-74.
38. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986: 73, 320-332.
39. Ohkoshi S. Detection of HBV DNA in non-A, non-B hepatic tissues using the polymerase chain reaction assay. Gastroenterol Jpn 1991: 26, 728-733.
40. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992: 15, 949-963.
41. Parkin DM, Stjernswrd J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull Wld Hlth Org 1984: 62, 163-182.
42. Paterlini P, Gerken G, Makajima E, Terre S, D'Enrico A, Grigioni N, Nalpas B, Franco D, Wands J, Kew M, Pisi E, Tiollais P, Brechot C. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Eng J Med 1990: 323, 80-85.
43. Pyong SJ, Tsukuma H, Hiyama T. Case-control study of hepatocellular carcinoma among Koreans living in Osaka. Japan. Jpn J Cancer Res 1994: 85, 674-679.
44. Rodriguez JW, Kirlin WG, Ferguson RJ, Doll MA, Gray K, Rustan RD, Lee ME, Kemp K, Urso P, Hein DW. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993: 67, 445-452.
45. Ruiz J, Sangro B, Cuendle JI, Beloqui O, Riezu-Boj JI, Herrero JI, Prieto J. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992: 16, 637-641.
46. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Pror Natl Acad Sci USA 1988: 85, 5240-5243.
47. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995: 21, 650-655.
48. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Ishibashi H. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukoaka, Japan. Int J Cancer 1992: 51, 509-514.
49. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, Tamai S, Hoshino H, Inoue T, Kanisawa M. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from antibody to hepatitis C virus-positive cirrhotic patients. Cancer 1994: 73, 1149-1154.
50. Trichopoulos D, Day NE, Kaklamani E, Tzonou A, Muñoz N, Zavitsano X, Koumantaki Y, Trichopoulos A. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987: 39, 45-49.
51. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Eng J Med 1993: 328, 1797-1801.
52. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolicactivation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 1991: 12, 1839-1845.
53. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA and Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with poor metabolizer phenotype. Pharmacogenetics 1991: 1, 26-32.
54. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5, 1-17.
55. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Tannenbaum SR. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994: 369, 154-156.
56. Yanagawa Y, Sawada M, Deguchi T, Gonzalez FJ, Kamataki T. Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells; mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Cancer Res 1994: 54, 3422-3427.